Clinical Trial: An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition

U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07019194) titled 'An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition' on May 23.

Brief Summary: An Open-label, Randomized, Single-dose, Two-way Crossover Bioequivalence Study to Compare Two Strengths (10 mg and 20 mg) of Senaparib Capsules in Healthy Chinese Subjects Following Oral Administration Under Fasting Condition

Study Start Date: June 21, 2024

Study Type: INTERVENTIONAL

Condition: Solid Tumor

Intervention: DRUG: Senaparib capsules(20mg)

Single oral dose of Senaparib administered under fasting condition, 1*20mg capsules in first intervention period and then 2*10mg cap...